Art

J-GLOBAL ID：201802291221685494   Reference number：18A0269872

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

食道へん平上皮癌に対するNivolumab治療:非盲検,多施設,第2相試験【Powered by NICT】

Author (19)： Kudo Toshihiro (Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan) ,  Hamamoto Yasuo (Keio Cancer Centre, Keio University School of Medicine, Tokyo, Japan) ,  Kato Ken (Gastrointestinal Medical Oncology Division, National Cancer Centre Hospital, Tokyo, Japan) ,  Ura Takashi (Department of Clinical Oncology, Aichi Cancer Centre Hospital, Nagoya, Japan) ,  Kojima Takashi (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Centre Hospital East, Kashiwa, Japan) ,  Tsushima Takahiro (Division of Gastrointestinal Oncology, Shizuoka Cancer Centre, Shizuoka, Japan) ,  Hironaka Shuichi (Clinical Trial Promotion Department, Chiba Cancer Centre, Chiba, Japan) ,  Hara Hiroki (Department of Gastroenterology, Saitama Cancer Centre, Saitama, Japan) ,  Satoh Taroh (Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan) ,  Iwasa Satoru (Gastrointestinal Medical Oncology Division, National Cancer Centre Hospital, Tokyo, Japan) ,  Muro Kei (Department of Clinical Oncology, Aichi Cancer Centre Hospital, Nagoya, Japan) ,  Yasui Hirofumi (Division of Gastrointestinal Oncology, Shizuoka Cancer Centre, Shizuoka, Japan) ,  Minashi Keiko (Clinical Trial Promotion Department, Chiba Cancer Centre, Chiba, Japan) ,  Yamaguchi Kensei (Department of Gastroenterology, Saitama Cancer Centre, Saitama, Japan) ,  Yamaguchi Kensei (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan) ,  Ohtsu Atsushi (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Centre Hospital East, Kashiwa, Japan) ,  Ohtsu Atsushi (Exploratory Oncology Research and Clinical Trial Centre, National Cancer Centre, Kashiwa, Japan) ,  Doki Yuichiro (Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan) ,  Kitagawa Yuko (Department of Surgery, Keio University School of Medicine, Tokyo, Japan)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 18  Issue： 5  Page： 631-639  Publication year： 2017 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Nivolumab is a human monoclona...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0269872&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： esophageal tumor ,  patient ,  adenocarcinoma ,  *squamous cell carcinoma ,  *phase 2 study ,  drug therapy ,  intravenous administration ,  antibody ,  pneumonia ,  evaluation criterion ,  anorexia ,  follow-up study ,  protein ,  safety
Semi thesaurus term： 有害事象 , 【Automatic Indexing@JST】

JST classification (1)： Treatment for tumors in general  (GE03031L)

Terms in the title (6)： 食道へん平上皮癌 ,  Nivolumab ,  治療 ,  盲 ,  施設 ,  第2相試験